Cited 0 times in
Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곡지호 | - |
dc.contributor.author | 배숭준 | - |
dc.contributor.author | 안성귀 | - |
dc.contributor.author | 정준 | - |
dc.contributor.author | 지정환 | - |
dc.contributor.author | 차윤진 | - |
dc.date.accessioned | 2021-12-28T17:01:05Z | - |
dc.date.available | 2021-12-28T17:01:05Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186895 | - |
dc.description.abstract | We assessed the impact of 21-gene Recurrence Score (RS) assay on chemotherapy decision-making according to binary clinical risk stratification in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. We included patients with tumors measuring 1-5 cm, N0-1, and HR+/HER2- breast cancer who underwent surgery followed by adjuvant treatment. The clinical risk was determined by a modified version of Adjuvant! Online. We performed propensity score matching (PSM) according to the application of 21-gene RS separately in the low and high clinical risk groups. Before PSM, 342 (39.0%) of 878 patients were classified as having high clinical risk. In the high clinical risk group, 21-gene RS showed a significantly reduced chemotherapy rate of 39.3%, without increasing the recurrence. After PSM, the 21-gene RS application significantly reduced chemotherapy rate by 34.0% in 200 patients with high clinical risk (21-gene RS application, 32.0% vs. no 21-gene RS application, 66.0%, p < 0.001). There was also no significant difference in RFS according to 21-gene RS status in the high clinical risk group (log-rank test, p = 0.467). These results support the usefulness of the 21-gene RS to reduce the chemotherapy rate without adversely affecting prognosis in a high clinical risk group. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Soong June Bae | - |
dc.contributor.googleauthor | Sung Gwe Ahn | - |
dc.contributor.googleauthor | Jung Hwan Ji | - |
dc.contributor.googleauthor | Chihhao Chu | - |
dc.contributor.googleauthor | Dooreh Kim | - |
dc.contributor.googleauthor | Janghee Lee | - |
dc.contributor.googleauthor | Yoon Jin Cha | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.identifier.doi | 10.3390/cancers13164003 | - |
dc.contributor.localId | A06143 | - |
dc.contributor.localId | A05345 | - |
dc.contributor.localId | A02231 | - |
dc.contributor.localId | A03727 | - |
dc.contributor.localId | A06110 | - |
dc.contributor.localId | A04001 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 34439158 | - |
dc.subject.keyword | 21-gene recurrence score | - |
dc.subject.keyword | adjuvant treatment | - |
dc.subject.keyword | breast neoplasms | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | clinical risk | - |
dc.contributor.alternativeName | Chu, Chihhao | - |
dc.contributor.affiliatedAuthor | 곡지호 | - |
dc.contributor.affiliatedAuthor | 배숭준 | - |
dc.contributor.affiliatedAuthor | 안성귀 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.contributor.affiliatedAuthor | 지정환 | - |
dc.contributor.affiliatedAuthor | 차윤진 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 4003 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.13(16) : 4003, 2021-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.